The patented uses of D-ribose in cardiovascular diseases

Recent Patents on Cardiovascular Drug Discovery

Volumn 5, Issue 2, 2010, Pages 138-142

  Shecterle, Linda M ^a   Terry, Kathleen R ^b   Cyr St , John A ^a  

^a Jacqmar Inc   (United States)

^b Intellectual Property Attorney   (United States)

Author keywords

Cardiovascular diseases; Congestive heart failure; D ribose; Energy; Function; Myocardial ischemia; Quality of life Therapeutic benefits

Indexed keywords

ADENOSINE TRIPHOSPHATE; DEOXYRIBOSE; PLACEBO; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; RIBOSE;

ARTICLE; CARBOHYDRATE METABOLISM; CARDIOVASCULAR DISEASE; CELL PROTECTION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIARRHEA; DIET SUPPLEMENTATION; DRUG MEGADOSE; ENERGY METABOLISM; GASTROINTESTINAL SYMPTOM; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; LOOSE FECES; NAUSEA; NONHUMAN; PATENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; QUALITY OF LIFE; ANIMAL; CARDIOVASCULAR DISEASES; CLINICAL TRIAL (TOPIC); COMPLICATION; DRUG SCREENING; HEART FAILURE; HEART MUSCLE; MALE; METABOLISM; MYOCARDIAL ISCHEMIA;

ADENOSINE TRIPHOSPHATE; ANIMALS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DIETARY SUPPLEMENTS; DRUG EVALUATION, PRECLINICAL; ENERGY METABOLISM; HEART FAILURE; HUMANS; MALE; MYOCARDIAL ISCHEMIA; MYOCARDIUM; PATENTS AS TOPIC; RIBOSE;

EID: 77953853322     PISSN: 15748901     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489010791515241     Document Type: Article

References (36)

1. Goodale WT, Olson RE, Hackel DB. The effect of fasting and cardiac failure upon heart muscle metabolism in man. J Clin Invest 1950; 29(6): 816.
2. Ingwall JS, Weiss RG. Is the failing heart energy starved? On using chemical energy to support cardiac function. Circ Res 2004; 95: 135-45.
3. Neubauer S. The failing heart - an engine out of fuel. N Engl J Med 2007; 356(11): 1140-51.
4. Redfield MM, Jacobson SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community. Appreciating the scope of the heart failure epidemic. JAMA 2003; 289(2): 194-202.
5. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American College of Chest Physicians; International Society for Heart and Lung Transplantation; Heart Rhythm Society. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): Develop in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm society. Circ 2005; 112(12): e154-e235.
6. Website of the American Heart Association. www. americanheartassociation.com
7. Adigum AZ, Rist KE. Cardiac resynchronization therapy for treatment of congestive heart failure. Hosp Physician 2005; 15-17: 24.
8. Baliga RR, Young JB, Eds. Energizing diastole. Heart Fail Clin 2008; 4: ix-xii.
9. Pauly DF, Pepine CJ. D-ribose as a supplement for cardiac energy metabolism. J Cardiovasc Pharmacol Ther 2000; 5(4): 249-58.
10. Kriett JM, Ward HB, Bianco RW, Einzig S, Alyono D, Anderson RW, et al. Recovery of adenine nucleotides and cardiac function following ischemia. Circulation 1983; 68(III): 389.
11. Mauser M, Hoffmeister HM, Nienaber C, Schaper W. Influence of ribose, adenosine and "AICAR" on the rate of myocardial adenosine triphosphate synthesis during reperfusion after coronary artery occlusion in the dog. Circ Res 1985; 56: 220-30.
12. Nienaber C, Mauser M, Schaper W. Stimulation of myocardial adenine nucleotide synthesis by postischemic reperfusion with direct purine precursor AICAR (5-amino-4-imidazole-carboxamide-riboside) caomparison with ribose. J Am Coll Card 1983; 1: 667.
13. Foker JE, Einzig S, Wang T. Adenosine metabolism and myocardial preservation. Consequences of adenosine catabolism on myocardial high-energy compounds and tissue blood flow. J Thorac Cardiovasc Surg 1980; 80: 506-616.
14. St Cyr JA, Bianco RW, Schneider JR, Mahoney JR Jr, Tveter K, Einzig S, et al. Enhanced high energy phosphate recovery with ribose infusion after global myocardial ischemia in a canine model. J Surg Res 1989; 46(2): 157-62.
15. Zimmer HG. Normalization of depressed heart function in rats by ribose. Science 1983; 220(4592): 81-2.
16. Zimmer HG. Significance of the 5-phosphoribosyl-1-pyrophos-phate pool for cardiac purine and pyrimidine nucleotide synthesis: Studies with ribose, adenine, inosine, and orotic acid in rats. Cardiovasc Drug Ther 1998; 12: 179-87.
17. PDR Health. D-ribose. PDR internet information. Website: www.pdrhealth.com/drug_info/nmdrugprofiles/nutsupdrugs/dri_0226.shtml
18. Gross M, Zollner N. Serum levels of glucose, insulin, and C-peptide during long term D-ribose administration in man. Klin Wochenschr 1991; 69: 31-6.
19. Griffiths JC, Borzelleca JL, St. Cyr J. Lack of oral embryoto-xicity/teratogenicity with D-ribose in Wistar rats. J Food Chem Toxicol 2007; 45(3): 388-95.
20. Griffiths JC, Borzelleca JL, St. Cyr J. Sub-chronic (13 week) oral toxicity study with D-ribose in Wistar rats. J Food Chem Toxicol 2007; 45(1): 144-52.
21. Zimmer HG. Normalization of depressed heart function in rats by ribose. Science 1983; 220(4592): 81-2.
22. Zimmer HG, Ibel H, Suchner U, Schad H. Ribose intervention in the cardiac pentose phosphate pathway is not specie-specific. Science 1984; 223(4637): 712-4.
23. Schneider JR, St. Cyr JA, Mahoney JR, Bianco RW, Ring WS, Foker JE. Recovery of ATP and return of function after global ischemia. Circulation 1985; 72(4): III-298.
24. Pliml W, Von Armin T, Stablein A, Hofmann H, Zimmer HG, Eerdmann E. Effects of ribose on exercise-induced ischaemia in stable coronary artery disease. Lancet 1992; 340: 507-10.
25. Perlmutter NS, Wilson RA, Angello Da, Palac RT, Lin J, Brown BG. Ribose facilitates thallium-201 redistribution in patients with coronary artery disease. J Nucl Med 1991; 32(2): 193-200.
26. Sawada SG, Lewis S, Kovacs R, Khouri S, Gradus-Pizlo I, St. Cyr J, et al. Evaluation of the anti-ischemic effects of D-ribose during dobutamine stress echocardiography: A pilot study. Cardiovasc Ultrasound 2009; 7: 5.
27. Vance RA, Einzig S, Kreisler K, St. Cyr J. D-ribose maintains ejection fraction following aortic valve surgery. FASEB J 2000; 14(4): A419.
28. Perkowski D, Wagner S, St Cyr J. D-ribose and "off" pump coronary artery bypass revascularization aids cardiac indices following acute myocardial infarction. Proceedings from the 11th Annual New Era Cardiac Care: Innovation and Technology. San Diego 2008.
29. Omran H, Illien S, MacCarter D, St Cyr J, Luderitz B. D-ribose improves diastolic function and quality of life in congestive heart failure patients: A prospective feasibility study. Eur J Heart Fail 2003; 5: 615-9.
30. Carter O, MacCarter D, Mannebach S, Biskupiak J, Stoddard G, Gilbert EM, et al. D-ribose improves peak exercise capacity and ventilatory efficiency in heart failure patients. J Am Coll Cardiol 2005; 45 (3 Suppl A): 185A.
31. Vijay N, MacCarter D, Shecterle LM, St Cyr JA. Letter to the Editor. D-ribose benefits heart failure patients. J Med Food 2008; 11(1): 199-200.
32. MacCarter D, Vijay N, Washam M, Shecterle LM, Sierminski H, St Cyr JA. Letter to the Editor. D-ribose aids advanced ischemic heart failure patients. Int J Cardiol 2009; 137(1): 79-80.
33. Seifert JG, Subudhi AW, Fu MX, Riska KL, John JC, Shecterle LM, et al. The role of ribose on oxidative stress during hypoxic exercise: a pilot study. J Med Food 2009; 12(3): 690-3.
34. St. Cyr, J., Johnson, C. Compositions for increasing energy in vivo. US6159942 (2000).
35. Butler, T.L., St. Cyr, J., Johnson, C.A. Methods for improving cardiac function. US7553817 (2009).
36. St. Cyr, J.A., Perkowski, D.J. Use of ribose for recovery from anesthesia. US20090197818 (2009).